Hepatocellular recurrence after orthotopic liver transplantation: Is combination of α-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation.
作者信息
Hashemi Mohammad, Ghavami Saeid
机构信息
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran.
出版信息
Hepat Mon. 2011 Mar;11(3):155-6.
Abstract
摘要
相似文献
1
2
Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Technol Cancer Res Treat. 2016 Dec;15(6):780-786. doi: 10.1177/1533034615605248. Epub 2015 Sep 14.
3
Liver transplantation for hepatocellular carcinoma: one center's experience, 1987-1994.
J Transpl Coord. 1996 Sep;6(3):145-7. doi: 10.7182/prtr.1.6.3.c0h0633x32043273.
4
Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation.
Surgery. 2017 Mar;161(3):830-836. doi: 10.1016/j.surg.2016.08.049. Epub 2016 Oct 19.
5
Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
Surgery. 2017 Dec;162(6):1250-1258. doi: 10.1016/j.surg.2017.08.007. Epub 2017 Oct 13.
6
Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
J Gastroenterol Hepatol. 2014 Mar;29(3):597-602. doi: 10.1111/jgh.12461.
7
Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
Medicine (Baltimore). 2016 Jan;95(3):e2478. doi: 10.1097/MD.0000000000002478.
8
α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Hum Pathol. 2012 Nov;43(11):1955-63. doi: 10.1016/j.humpath.2011.11.022. Epub 2012 Apr 17.
9
Tumor Characteristics and Long-Term Outcome of Incidental Hepatocellular Carcinoma After Orthotopic Liver Transplant.
Exp Clin Transplant. 2015 Aug;13(4):333-8.
10
[Study on the value of serum des-γ-carboxy prothrombin in predicting hepatocellular carcinoma recurrence after liver transplantation].
Zhonghua Gan Zang Bing Za Zhi. 2020 Nov 20;28(11):918-923. doi: 10.3760/cma.j.cn501113-20201009-00545.
引用本文的文献
1
Elevated expression levels of androgen receptors and matrix metalloproteinase-2 and -9 in 30 cases of hepatocellular carcinoma compared with adjacent tissues as predictors of cancer invasion and staging.
Exp Ther Med. 2015 Mar;9(3):905-908. doi: 10.3892/etm.2014.2150. Epub 2014 Dec 19.
2
Different faces of hepatocellular carcinoma as a health threat in 21st century.
Hepat Mon. 2013 Feb 4;13(2):e9308. doi: 10.5812/hepatmon.9308. Print 2013 Feb.
3
Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence.
Iran J Radiol. 2012 Nov;9(4):167-77. doi: 10.5812/iranjradiol.8242. Epub 2012 Nov 20.
本文引用的文献
1
2
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
J Clin Oncol. 2009 Dec 1;27(34):5734-42. doi: 10.1200/JCO.2009.23.1282. Epub 2009 Oct 5.
3
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.
J Clin Oncol. 2009 Jan 20;27(3):446-52. doi: 10.1200/JCO.2008.18.8151. Epub 2008 Dec 8.
4
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients.
World J Gastroenterol. 2006 Dec 7;12(45):7319-25. doi: 10.3748/wjg.v12.i45.7319.
5
Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan.
J Gastroenterol Hepatol. 2006 Oct;21(10):1561-6. doi: 10.1111/j.1440-1746.2006.04425.x.
6
Serum tumor markers for detection of hepatocellular carcinoma.
World J Gastroenterol. 2006 Feb 28;12(8):1175-81. doi: 10.3748/wjg.v12.i8.1175.
7
Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma.
Mol Diagn. 2004;8(4):207-12. doi: 10.1007/BF03260065.
8
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Gastroenterology. 2003 Jul;125(1):89-97. doi: 10.1016/s0016-5085(03)00689-9.
9
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Biochem Biophys Res Commun. 2003 Jun 20;306(1):16-25. doi: 10.1016/s0006-291x(03)00908-2.
10
Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?
Transplantation. 2002 Dec 27;74(12):1746-51. doi: 10.1097/00007890-200212270-00017.
Zotero 插件